US EditionLandmark Data From Rutgers Cancer Institute and RWJBarnabas Health Show Long-Term Complete Responses of T Cell Therapies for HPV-Related Cancers
Two studies at Rutgers show durable responses in HPV-related cancers, including complete remission in some patients lasting up to 12 years, signaling potential long-term cures.
- At the SITC Annual Meeting Nov 5–9, 2025, Christian Hinrichs, MD presented findings showing durable T cell responses and complete regressions in HPV-associated cancers, with six of 10 patients responding.
- Facing limited options, researchers at Rutgers pursued engineered cell therapies for metastatic HPV-associated epithelial cancers through collaborative development with the National Cancer Institute and on-site GMP facility at Rutgers Cancer Institute.
- Using a single infusion of up to 50 billion E7 T cells, 10 patients in a Phase II trial showed tumor shrinkage in six and two complete regressions ongoing at 11 and 12 months, respectively.
- Dr. Christian Hinrichs, MD said `These studies indicate that one-time cell therapies can achieve durable responses in epithelial cancers, which historically have been more resistant to these treatments than blood cancers`, and Sue, patient from Washington, DC, described being cancer-free 12 years after treatment.
- With statewide reach, RWJBarnabas Health cares for more than five million people annually and operates 14 hospitals and the Rutgers Cancer Institute, New Jersey's only NCI-designated Comprehensive Cancer Center.
40 Articles
40 Articles
T cell therapies show long-term HPV gains
Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI)—designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes of Health, announced findings from two HPV-related studies that highlight the potential of novel T cell therapies to achieve long-lasting remission and complete tumor regression in patients with adv…
LoudounTimes.com
Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-term Complete Responses of T Cell Therapies for HPV-Related Cancers
Two presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting highlight promising new clinical trial results
This Breakthrough Clinical Trial Is Saving Cancer Patients Out Of Options
Rutgers Cancer Institute of New Jersey is reporting major progress in the fight against advanced HPV-related cancers, with new cell therapies showing complete tumor regression (and even decade-long remission) in patients who had no options…
Studies show that certain intimate practices can transmit the human papilloma virus (HPV). Some types of viruses increase the risk of cancer in the mouth and throat.
Pre-Clinical Insights from IO Biotech Advancements in Therapeutic Cancer Vaccine Candidates Presented at SITC 2025
'Abstract' At the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), IO Biotech presented compelling pre-clinical data on its additional therapeutic cancer vaccine candidates. This research highlights the company's commitment to advancing immunotherapeutic approaches in oncology. Alongside this, recent market performance indicators suggest a positive outlook for IO Biotech, outperforming broader market trends and demonstratin…
MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting
As immunotherapy continues to transform cancer care, researchers at The University of Texas MD Anderson Cancer Center are sharing new insights at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting about how the immune system can be trained, guided and strengthened to improve patient outcomes.
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
